BacThera is a 50/50 joint venture between Lonza AG and Chr. Hansen to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. It operates from its headquarters in Basel (CH) and has production facilities in Denmark and Switzerland.
Bacthera brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of live bacteria strains for therapeutic use. While Chr. Hansen contributes its extensive know-how in developing, upscaling and manufacturing live bacteria strains, Lonza brings strong capabilities in pharma contract manufacturing and outstanding formulation and drug delivery technologies, including the unique enTRinsic™ capsules.